Imricor Secures US FDA Clearance for NorthStar Mapping System; Shares Hit Five-Year High
MT Newswires Live
Jan 29
Imricor Medical Systems (ASX:IMR) said that the US Food and Drug Administration (FDA) has cleared its NorthStar Mapping System, marking the company's second FDA clearance in January, following earlier approval of the VisionMR Diagnostic Catheter, according to a Thursday filing with the Australian bourse.
The approval allows the company to market NorthStar in the US, establishing it as the core system of interventional cardiac magnetic resonance imaging (MRI) labs, with further approvals anticipated as the company expands its MRI-guided electrophysiology platform, the filing added.
The company's shares rose 12% in recent Thursday trade, earlier hitting a five-year high.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.